A Phase 1 First-in-Human Study of AMG 330, an Anti-CD33 Bispecific T-Cell Engager (BiTE (R)) Antibody Construct, in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

Ravandi Farhad; Stein Anthony S.; Kantarjian Hagop M.; Walter Roland B.; Paschka Peter; Jongen-Lavrencic Mojca; Ossenkoppele Gert J.; Yang Zhao; Mehta Bhakti; Subklewe Marion

首页> 外文期刊>Blood: The Journal of the American Society of Hematology >A Phase 1 First-in-Human Study of AMG 330, an Anti-CD33 Bispecific T-Cell Engager (BiTE (R)) Antibody Construct, in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

【24h】

A Phase 1 First-in-Human Study of AMG 330, an Anti-CD33 Bispecific T-Cell Engager (BiTE (R)) Antibody Construct, in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

机译：AMG 330的第1阶段第一人体研究，抗CD33双特异性T细胞参录手（咬合（R））抗体构建体，复发/难治性急性髓性白血病（R / R AML）

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Blood: The Journal of the American Society of Hematology》 |2018年第novaelatreatmentappr期|共4页
作者
Ravandi Farhad; Stein Anthony S.; Kantarjian Hagop M.; Walter Roland B.; Paschka Peter; Jongen-Lavrencic Mojca; Ossenkoppele Gert J.; Yang Zhao; Mehta Bhakti; Subklewe Marion;
展开▼
作者单位

Univ Texas MD Anderson Canc Ctr Dept Leukemia Houston TX 77030 USA;

City Hope Natl Med Ctr Gehr Family Ctr Leukemia Res Duarte CA USA;

Univ Texas MD Anderson Canc Ctr Dept Leukemia Houston TX 77030 USA;

Fred Hutchinson Canc Res Ctr Clin Res Div 1124 Columbia St Seattle WA 98104 USA;

Ulm Univ Med Ctr Ulm Germany;

Erasmus Univ Med Ctr Rotterdam Rotterdam Netherlands;

Univ Med Ctr Amsterdam Netherlands;

Amgen Inc Thousand Oaks CA 91320 USA;

Amgen Inc Thousand Oaks CA 91320 USA;

Ludwig Maximilians Univ Munchen Lab Leukemia Diagnost Dept Internal Med 3 Univ Hosp Munich;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类血液及淋巴系疾病;
关键词

相似文献

外文文献
中文文献
专利

1. A Phase 1 First-in-Human Study of AMG 330, an Anti-CD33 Bispecific T-Cell Engager (BiTE (R)) Antibody Construct, in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) [J] . Ravandi Farhad, Stein Anthony S., Kantarjian Hagop M., Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：AMG 330的第1阶段第一人体研究，抗CD33双特异性T细胞参录手（咬合（R））抗体构建体，复发/难治性急性髓性白血病（R / R AML）
2. Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2x2) CD33/CD3 T-Cell Engager, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) [J] . Westervelt Peter, Roboz Gail J., Cortes Jorge E., Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：AMV564的第1阶段先试验，一只二价双特异性（2x2）CD33 / CD3 T细胞参录，在复发/难治性急性髓性白血病（AML）的患者中
3. A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE~?) antibody construct, in patients with refractory solid tumors [J] . Maxim Kebenko, Marie-Elisabeth Goebeler, Martin Wolf, Oncoimmunology. . 2018,第8期

机译：在难治性固体肿瘤患者中，Solitomab（MT110，AMG 110），双特异性EPCAM / CD3 T细胞（咬合〜β）抗体构建体的多中心阶段1研究
4. Design and Characterization of Bispecific Chemically Self-Assembled Antibody Nanoring(CSAN) T-Cell Engagers That Target CD22+ B- Leukemias or Lymphomas [C] . Jingjing Shen, Adrian Fegan, Daniel A. Vallera, PEGS . 2015

机译：靶向CD22 + B-白血病或淋巴瘤的双特化学自组装抗体纳米（CSAN）T细胞啮合的设计与表征
5. Comparative pharmacology of the human CD19/CD3 Bispecific T-cell engager (BiTERTM) antibody blinatumomab with the hybrid murine surrogate CD19/CD3 BiTE antibody hyS103. [D] . Fuhrmann, Stacy R. 2010

机译：人CD19 / CD3双特异性T细胞衔接子（BiTERTM）抗体blinatumomab与杂种鼠替代CD19 / CD3 BiTE抗体hyS103的比较药理学。
6. A multicenter phase 1 study of solitomab (MT110 AMG 110) a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct in patients with refractory solid tumors [O] . Maxim Kebenko, Marie-Elisabeth Goebeler, Martin Wolf, 2018

机译：索利妥单抗（MT110AMG 110）是双特异性EpCAM / CD3 T细胞衔接子（BiTE®）抗体构建物的多中心1期研究用于难治性实体瘤患者
7. A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct, in patients with refractory solid tumors [O] . Maxim Kebenko, Marie-Elisabeth Goebeler, Martin Wolf, 2018

机译：在难治性固体肿瘤患者中，Solitomab（MT110，AMG 110），双特异性EPCAM / CD3 T细胞（BITE®）抗体构建体的多中心阶段1研究

A Phase 1 First-in-Human Study of AMG 330, an Anti-CD33 Bispecific T-Cell Engager (BiTE (R)) Antibody Construct, in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

著录项

相似文献

相关主题

期刊订阅